Atara Biotherapeutics Inc., of South San Francisco, said the EMA granted orphan drug designation for the company's allogeneic Epstein-Barr virus (EBV)-targeted cytotoxic T-lymphocyte product candidate for the treatment of patients with EBV post-transplant lymphoproliferative disorder.